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Summary The prognosis of colorectal cancer has not significantly changed during the last 30 years. While evaluation of tumour cell
proliferation may provide prognostic information, results obtained so far have been contradictory. Heterogeneity in tumour cell proliferation
may explain these contradictions. With in vivo injection of iododeoxyuridine (IdUrd), estimation of labelling index (LI), S-phase transit time (Ts)
and potential doubling time (Tpot) may be performed from a single sample. A total of 109 colorectal cancers were studied after in vivo injection
of IdUrd before surgical removal. From each cancer, four to eight samples were processed for both flow cytometrical (FCM) and
immunohistochemical (IHC) visualization of IdUrd incorporation. Ll/IHC was morphometrically quantified at both the luminal border and the
invasive margin of these tumours. LI was significantly higher at the luminal border compared with the invasive margin, although they were
correlated with each other. Using combined IHC and FCM methods, rapidly growing colorectal cancers (high Li and/or low Tpot) showed an
increased survival (significant for LI at the invasive margin and for 7pt at both the invasive margin and the luminal border) in the entire
unselected material and for radically removed Dukes' B tumours. FCM data alone did not discriminate for survival, with the exception of T5 in
diploid and radically removed Dukes' B tumours.
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Colorectal cancer is the second leading cause of cancer death in
most countries with a western type of diet. Treatment is still based
on surgical removal ofthe tumours, and prognosis has not changed
much during the last 30 years; approximately 50% ofpatients with
colorectal cancer die from their disease. Nevertheless, clinical trials
in recent years have shown that both adjuvant chemotherapy
(IMPACT investigators, 1995; Moertel et al, 1995) and treatment
with monoclonal antibodies (Riethmulleret al, 1994) might improve
the survival in patients with Dukes' C colorectal cancer. In addition,
other studies have shown that the surgical technique is important for
prognosis (MacFarlane et al, 1993) and that preoperative radio-
therapy reduces the risk oflocal recurrence (Holm et al, 1994).
So far, Dukes' classification of tumour stage is the most impor-
tant prognostic factor and few other tissue derived alterations that
correlate with the clinical outcome of colorectal cancer exist.
Identification ofspecific, independent biological parameters corre-
lating with biological tumour behaviour could in the future guide
clinicians in selecting patients for both chemo- and radiotherapy.
Malignant tumours with a rapid cell proliferation may be candi-
dates for treatment with altered radiotherapy schedules (Dische
and Saunders, 1989) and, for similar reasons, they may be more
susceptible to chemotherapy (Riccardi et al, 1991). In this respect,
several factors, such as S-phase (Bauer et al, 1993), proliferative
cell nuclear antigen (PCNA) (Al-Sheneber et al, 1993; Teixeira et
al, 1994) and Ki-67 (Kubota et al, 1992; Baretton et al, 1996) are
of interest. The results obtained so far are contradictory for
colorectal cancer. There are, however, indications that rapid
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tumour cell proliferation might be correlated with poorer prog-
nosis (Bauer et al, 1987; Harlow et al, 1991).
Multiple parameters associated with tumour cell proliferation
can be measured by in vivo injection ofbromo- (BrdUrd) or iodo-
deoxyuridine (IdUrd), and dual-parameter flow cytometric
analysis of a single sample (Begg et al, 1985). This technique
allows determination of labelling index (LI), the duration of S-
phase (T") and potential doubling time (T0t) in colorectal cancer
(Rew et al, 1991; Wilson et al, 1993a and b; Terry et al, 1995). LI
can be evaluated either by FCM of cell suspensions or by
morphometry in immunohistochemically (IHC) stained tissue
sections. T can thus be calculated with LI derived either from
histology or from FCM (Bennett et al, 1992). The findings by
Dische and Saunders (1989), Rew et al (1991) and Wilson (1991)
suggest that cell proliferation evaluated with this technique might
be ofindependent prognostic value.
Colorectal cancer show a marked intratumoral heterogeneity
with respect to several parameters, such as DNA content (Koha et
al, 1990) and histological differentiation (Jass et al, 1986), and to
proliferative parameters, such as S-phase fraction (Lindmark et al,
1991), PCNA (Teixeira et al, 1994) and expression of Ki-67
(Shepherd et al, 1988). Wilson et al (1993b) used flow cytometry
alone to measure T , and have also described intratumoral hetero- pot
geneity in colorectal cancers. In addition, Taniyama et al (1993)
have reported that mainly moderately differentiated colorectal
cancer can be poorly differentiated at the invasive margin and that
such tumour regions can also differ with respect to proliferative
activity and tumour spread.
The aim of this study was (1) to evaluate whether there is a
systematic heterogeneity with respect to cell proliferation between
deep (invasive margin) and superficial (luminal border) parts of
colorectal cancers and (2) to investigate the prognostic impact of
LI, T and Tpt.
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MATERIAL AND METHODS
Patients
One hundred and nine patients with colorectal cancer who under-
went surgery at the University Hospital ofUme'a (71 patients) and
at the district hospitals of Ornskoldsvik (13), Lycksele (9), Pite'a
(10) and Lule'a (6) within the northern healthcare region ofSweden
were prospectively included in the study. After hospital ethical
committee approval, informed consent was obtained from the
patients. Intravenous infusion of a single dose of 100 mg of IdUrd
dissolved in 100 ml of 0.9% saline was given at a median of 5.2 h
(range 1.1-8.9 h) before surgery. At the University Hospital of
Ume'a, fresh unfixed tumours were transported immediately after
removal to the Department of Clinical Pathology for further
processing. Each tumour was systematically sampled by dividing
the tumour into equal numbers of central and peripheral regions,
with at least four regions in total. From each of these regions,
adjacent samples were taken for routine histological evaluation,
morphometric analysis ofLI in IHC-stained tissue sections and for
flow cytometric analysis ofcell kinetic relations, i.e. LI, T and T ot
(Figure 1). At the district hospitals, one central and one peripheral
tumour sample was taken for flow cytometric analysis. However,
for routine histological evaluation and morphometric analysis of
LI in tissue sections, a minimum of four samples were systemati-
cally collected from both central and peripheral tumour regions.
Of the 109 patients with colorectal cancer included in the study,
53 were men and 56 were women. Twenty-five tumours were
classified as Dukes' stage A, 45 as Dukes' B and 39 as Dukes' C.
Ninety out of 109 tumours were classified as radically removed, of
which 25 were Dukes' stage A, 39 Dukes' B and 26 Dukes' C.
Colorectal cancer primary sites were distributed with an expected
frequency, i.e. 37 rectal, 26 sigmoid and 21 caecal cancers. The
remaining 24 tumours were located in the ascending, transverse
and descending colon.
All follow-up data were obtained by AO. The follow-up time of
living patients ranged from 18 to 78 months, with a median of 37
months. To verify the accuracy of cancer-specific survival used in
this study, curves ofcancer-specific survival for the entire material
(n = 109) were compared with relative survival data, i.e. death
rates of the colorectal cancer group compared with death rates
of a corresponding normal population. The two survival curves
showed good agreement. In addition, the survival curve for the
group ofpatients treated at the district hospitals corresponded well
with the survival curve from patients treated at the University
Hospital ofUme'a.
Flow cytometric analysis of IdUrd nuclear incorporation
The rod-shaped tissue samples ofsize 3-5 x 3-5 x 10-20 mm, taken
for FCM analyses from each colorectal carcinoma, were immedi-
ately fixed in 70% ethanol and then stored at 4°C until analysis.
Before FCM processing, one piece oftissue from each ofthese spec-
imens was minced into smaller pieces, subsequently digested using
0.4 mg ml-' pepsin (Sigma Chemical, St Louis, MO, USA) in 0.1 M
hydrochloric acid at 37°C for 30 min during continuous agitation
and filtered through a50-gmnylon mesh (Nylander et al, 1994). The
concentration ofnuclei was adjusted to 2 x 106 ml-' and the solution
centrifuged for 5 min at 2000 r.p.m. to sediment the nuclei. The
resulting nuclear pellet was partly denatured in 2 ml of
2 M hydrochloric acid for 15 min. The denaturation process was
stopped by addition of 2.5 ml of borax (JT Baker Chemical,
Phillipsburg, NJ, USA) in 2.5 ml of phosphate-buffered saline
(PBS) added with 0.5% Tween 20 (Sigma Chemical). After a wash
in PBS, the cell suspension was incubated at room temperature for
30 min with a BrdUrd/IdUrd monoclonal antibody diluted 1:20
(Dakopatts, Denmark), washed in PBS and incubated with fluores-
cein isothiocyanate- (FITC) conjugated rabbit anti-mouse F(ab)2
fragment (F313, Dako) (1:50 dilution) for 30 min at room tempera-
ture. After a final wash in PBS, the pellet was resuspended in a
propidium iodide solution containing RNAase and left in the dark at
4°C for at least 30 min before analysis. The suspensions were
analysed on a FACScan flow cytometer (Becton Dickinson) using
the FACScan or LYSYS software (Becton Dickinson). Debris,
damaged cells and doublets were excluded by gating on a forward-
and side-scatter dot plot and on the FL2 width and FL2 area dot plot.
The analysis was performed so that the G, diploid peak was situated
near channel 200, with a tetraploid peak around 400. Normal
colorectal mucosa specimens from each patient were used as an
internal control. With ethanol-fixed material, as used in this study,
multipeak profiles were rare, and ploidy analysis using special soft-
ware algorithms was not necessary. From each specimen, 10 000
cells or more were analysed for Ts, LI/FCM and Tp)/FCM. LI/FCM
and T /FCM were calculated as suggested by Steel (1977), when X pot
was assumed to be 0.8 according to Wilson and McNally (1992).
Correction of LI/FCM for mitotic division from time of infusion
with IdUrd and to time for fixation was made according to a tech-
nique described by Lochrin et al (1992). According to the DNA
histogram calculation, the DNA index was determined and, ifone or
more samples from the same tumour were found to be aneploid, that
tumour was classified as aneuploid. In aneuploid tumours, LI/FCM
analyses was restricted to the aneuploid cell population. The CV
(coefficient ofvariation) ofthe DNA peaks for diploid cells in aneu-
ploid tumours had a mean value of 6.3 (range 2.8-10.6). The DNA
peaks ofaneuploid tumour cells had a mean CV of7.1 (2.9-12.4).
Immunohistochemical procedures
For histopathological analysis, a tumour sample cut perpendicular
to the mucosal surface was collected from each region (see above),
fixed overnight in 10% formalin buffered to neutrality with phos-
phate buffer and subsequently embedded in paraffin. The sample
included a section from the entire tumour, i.e. from the intestinal
lumen all the way to the submucosa, muscular layer or to the
t(h
Formalin / i Ethanol
Immunohistochemistry Flow cytometry
Figure 1 Schematic drawing that shows the sampling scheme used when
taking four pieces of tissue from one colorectal cancer
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Figure 2 Schematic cross-section of the large bowel showing the luminal
border and the invasive margin tumour compartments analysed. Luminal
border is defined as the most superficial fourth of the tumour depth within the
bowel wall. Invasive margin is defined as the deepest fourth
peripheral fat. Four-micrometre sections were cut from the
paraffin blocks (four from each tumour) and left to dry overnight at
37°C (Nylander et al, 1994), followed by 30 min at 56°C. After
dewaxing and rehydration, the slides were digested with 0.4%
pepsin in 0.01 M hydrochloric acid at 370C for 30 min, followedby
2 M hydrochloric acid treatment at room temperature for 20 min.
After rinsing in PBS, the slides were stained in an automated
immunostainer (Ventana ES, Ventana, Tucson, AZ, USA) using an
anti-IdUrd/BrdUrd monoclonal antibody (BrdU, Becton
Dickinson) at a dilution of 1:600. Antibody visualization was
performed according to the Ventana program. The slides were then
manually counterstained with Mayer's haematoxylin for 1.5 min.
The Ventana ES is constrained to perform all incubations at a400C
slide reaction temperature.
Morphometrical analysis
One IHC-stained section from each of the four tissue samples
(collected as described above) was used for morphometric
analysis. A Zeiss microscope (63 x objective magnification)
equipped with a square lattice in the eyepiece was used to define
the proper size ofthe counting frame in each ofthe tumours evalu-
ated (Gundersen et al, 1988). From each tumour about 40 fields of
vision were measured in a systematic random fashion, so that the
first field was selected at random while subsequent fields were
chosen systematically by adjusting the distance between indi-
vidual fields of vision roughly proportional to the overall area in
question.
Two tumour compartments were regularly evaluated in each
section. One was represented by the most superficial fourth (corre-
sponding to the luminal tumour part), while the other was
represented by the deepest fourth (corresponding to the invasive
margin) (Figure 2). The two compartments were analysed sepa-
rately without prior knowledge ofthe results from earlier morpho-
metrical evaluations.
Two unbiased counting frames (Gundersen, 1977) were chosen
within each of the 40 fields of vision. One of these frames was
used to count positive nuclei and the other to count negative
nuclei. These counts were then used to calculate the numerical
density of positive and negative nuclei. The labelling index was
calculated as:
Q I/A
LI/IHC=(Q/A ) + (QIAn)
(equation 1)
where Qp is the number of positive nuclei, Ap is the area of the
counting frame used to count positive nuclei, Q. is the number of
negative nuclei and A is the frame area used for counting the
negative nuclei. Only epithelial tumour nuclei were examined.
For each tumour, about 200 positive and 200 negative nuclei
were counted from both the most superficial (luminal border) and
the deepest (invasive margin) fourths. In practice, the intratumoral
coefficient of error (CE) of the numerical density for positive
nuclei for each defined tumour compartment (e.g. invasive
margin) was between 0.05 and 0.15. The technique ofLochrin et al
(1992) was used to correct LI for mitotic division from time of
infusion with IdUrd to time offixation.
With these procedures, LI was quantitatively evaluated as a
mean value for the entire tumour, using FCM analysis of nuclear
suspensions, and as an index for both luminal border (most super-
ficial fourth) and invasive margin (deepest fourth) in immuno-
histochemically stained sections from each tumour. TPO /IHC was
calculated according to Bennet et al (1992), using LI from either
the invasive margin or the luminal border:
Xx T
T /IHC = s
pot LI/IHC (equation 2)
Reliability ofquantitative results from morphometrical methods
(Gundersen and Osterby, 1981; Gundersen and Jensen, 1987)
depends on uniform sampling at all levels from a random system-
atic approach, however, in clinicopathological practice, such a
procedure is not always possible to achieve. In this study, all
sampling steps were performed in a uniform way, with the excep-
tion of the first step when a strict systematic sampling was used.
We therefore tested our sampling error in measuring LIIIHC using
four tumours that were sampled according to a strictly systematic
scheme and to a morphometrically correct random systematic
scheme. The comparison between the two sampling procedures
showed only a minor sampling error, with a CE for the difference
between the paired tumour samples of0.04.
Statistics
Spearmans correlation coefficient (r) and Wilcoxon matched-pairs
signed-rank test were used to compare sets ofparameters measured
on the same tumour. To compare distributions of a variable for
groups, the Kruskal-Wallis test was used. For morphometrical
analysis, CE was calculated according to methods described by
West et al (1990). Kaplan-Meier's method was used to estimate the
cancer-specific survival, and comparison between groups was
performed using the log-rank test. Death with known locoregional
or distant metastases was processed as an event and, if no event
occurred, the patient was censored at the time of the last clinical
follow-up. A P-value less than 0.05 was considered to be statisti-
cally significant. The median value or the highest/lowest quartiles
of the entire patient material were used as cut-off points to create
groups for comparison of different parameters. Statistical analyses
were performed using SPSS version 6.1.3 (SPSS, IL, USA).
RESULTS
Of the 109 colorectal cancers, 89 could be evaluated with flow
cytometry while 97 were analysed morphometrically. Ofthese, the
invasive margin could be evaluated in 97 and the luminal border in
94 of the cancers. All tumours in which light microscopic short-
comings prevented identification of the luminal border and/or the
invasive margin, and/or measurement of the distance between the
luminal border and the invasive margin were excluded. At least
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Figure 3 Paired observations of LI/IHC both at the luminal border and at the
invasive margin. LI/IHC was significantly higher at luminal border (P< 0.001).
Only nine tumours had higher LI at the invasive margin compared with the
luminal border
two tissue samples from each tumour had to be measurable for a
tumour to be included in the morphometrical study. Tumours
studied by flow cytometry alone, or by combined immunohisto-
chemically and flow cytometrically evaluated T , were also
excluded iftechnical problems prevented accurate recording ofthe
timespan between infusion of IdUrd and fixation ofthe tumour or
production ofadequate DNA profiles and/or dot plot diagrams.
LI
LI/IHC measured morphometrically was significantly higher atthe
luminal border compared with the invasive margin (P < 0.001)
(Figures 3 and4). Only nine tumours showed higherLI at the inva-
sive margin. Nevertheless, LIIIHC at the luminal border and the
invasive margin were correlated to each other (r = 0.66, P < 0.001;
Figure 5). No significant correlations were found for LI/IHC and
Dukes' stage, grade or topography. Furthermore, no significant
difference was observed between central and peripheral samples
regarding LI/FCM, either for Ts or for TPOt/FCM (P = 0.3, P = 0.8
and P = 0.7 respectively).
As expected, stage according to Dukes was a strong prognostic
indicator P < 0.001 (Figure 6). For the entire unselected tumour
material, colorectal cancers with low LI/IHC (below median
value) at the invasive margin tended to have poorer prognosis than
those with high LI/IHC. Tumours with very low LI/IHC at the
invasive margin (lowest quartile used as cut-off level) showed
significantly lower survivals (P = 0.02, Figure 7A). In radically
removed tumours, very low LI/IHC (lower quartile as cut-off
level) was associated with significantly lower survival rates than
those with higher LI/IHC. These results were generally valid for
all radically removed tumours (P = 0.01) and for radically
removed Dukes' B tumours (P = 0.01), although a small number
of tumours with low LI/IHC were recorded in the Dukes' B group
(Figure 7B). No differences in survival were seen in the Dukes' C
group. The survival pattern for LI/IHC at the luminal border was
Figure 4 Micrographs from two different compartments within the same
colorectal adenocarcinoma immunohistochemically stained for
iododeoxyuridine (IdUrd) showing (A) a higher fraction (LI) of labelled nuclei
at luminal border compared with (B) the invasive margin
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Figure 5 Correlation between Ll/IHC at luminal border and at invasive
margin. LI was significantly correlated between the two regions (r= 0.65,
P< 0.001)
similar to that observed for the invasive margin but the differences
were not statistically significant. LI measured with flow cytometry
(LI/FCM) did not accurately predict survival either within the
entire material or for radically removed Dukes' B tumours alone.
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Figure 6 Kaplan-Meier cancer-specific survival curves for Dukes' stages
A (-), B (--- -) and C (- - -) in 109 colorectal carcinomas
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Figure 7 Kaplan-Meier survival curves for LI/IHC at the invasive margin
of colorectal cancer. (A) Cancer-specific survival for the entire material
(P = 0.02, n = 97). (B) Cancer-specific survival of radically removed Dukes'
B tumours (P = 0.01, n = 37). - - -, LI above the lowest quartile; -, the lowest
quartile
Radically removed tumours in which the difference in the magni-
tude ofLIAIHC between the luminal border and the invasive margin
was large tended to have a favourable prognosis, although this trend
was not statistically significant (P = 0.07) when using the lowest
quartile as cut-off level. The difference in LI/IHC between the
luminal border and the invasive margin did not prognostically
discriminate patients with radically removed Dukes' B tumours.
T, and Tt
T AfIHC at the invasive margin significantly predicted survival.
Patients with very long T,/1IHC at the invasive margin (highest
quartile as cut-offlevel) had significantly lower survival rates both
in the entire unselected tumour material (P = 0.002, Figure 8A)
and in the group with radically removed Dukes' B colorectal
cancers (P < 0.001, Figure 8B). T A/IHC at the invasive margin
also discriminated for survival when the median value was used as
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Figure 8 Kaplan-Meier survival curves for potential doubling time (T /IHC)
at the invasive margin of colorectal cancer. (A) Cancer-specific survival for
the entire material (P= 0.002, n = 76). (B) Cancer-specific survival of
radically removed Dukes' B tumours (P< 0.001, n = 32). - - -, the highest
quartile; -, TP, below the highest quartile
cut-off point, although this was restricted to the group with radi-
cally removed Dukes' B colorectal cancers, and the significance
level was lower (P = 0.04).
Using the highest quartile as the cut-off level, TPOt/IHC at the
luminal border significantly predicted survival in the entire unse-
lected material and for patients with radically removed Dukes'B
tumours (P = 0.008 and P = 0.002 respectively). However, when
the median value was used as the cut-off level, T ,t/IHC at the
luminal border did not significantly predict survival.
Tpot analysed by flow cytometry alone did not discriminate for
survival, either generally or for radically removed Dukes' B
tumours. A borderline P-value was recorded for the entire unse-
lected material with the highest quartile as cut-offlevel (P = 0.05).
No survival discrimination was found either for overall radically
removed tumours or for radically removed Dukes' B tumours. T
did not discriminate for survival, with the exception of radically
removed Dukes' B tumours, when the upper quartile was used as
the cut-offlevel (P = 0.04).
DNA ploidy
Thirty-nine of the 90 flow cytometrically evaluated tumours were
diploid while the remaining 51 were classified as aneuploid.
LI/FCM was significantly (P = 0.001) lower for diploid than for
aneuploidcolorectal cancers (Table 1). Incontrast, significantly (P=
0.04) higher values ofLI/IHC were observed at the invasive margin
fordiploidcompared withaneuploidcancers. Diploid and aneuploid
tumours did not differ for LI/IHC at the luminal border. The magni-
tudes of the calculated absolute differences between LI/IHC at the
luminal border and at the invasive margin were significantly higher
in aneuploid than in diploid tumours (P = 0.001, Table 1).
British Journal ofCancer(1998) 77(6), 917-925
P = 0.02
1
1
0 CancerResearch Campaign 1998922 R Palmqvist etal
Table 1 Mean values for parameters associated with cell proliferation and clinicopathological characteristics in 109 colorectal cancers
n Li Diff. T. T-,
Inv Lum Fcm Li Inv Lum Fcm
(%) (%) (%) (%) (h) (days) (days) (days)
Sex
Male 53 9.1* 14.6* 10.3 5.3 8.1 4.6* 2.9 3.7
(7.2-10.9) (12.2-17.1) (8.2-12.4) (3.7-7.0) (6.9-9.3) (3.2-6.0) (1.9-3.9) (3.0-4.5)
Female 56 11.5 18.3 10.9 6.7 7.4 2.9 1.7 4.2
(9.9-13.1) (16.2-20.3) (8.9-12.8) (4.9-8.5) (6.6-8.3) (2.1-3.8) (1.3-2.1) (2.8-5.6)
Topography
Right colon 37 10.3 16.5 7.8*a 5.6 7.1 3.1 2.2 4.0
(8.3-12.2) (13.3-19.8) (6.4-9.2) (2.8-8.3) (6.1-8.1) (2.1-4.1) (1.4-3.0) (3.0-4.9)
Left colon 35 10.4 17.3 13.9 6.4 7.8 4.1 2.5 2.8
(8.0-12.8) (13.5-21.0) (10.6-17.2) (3.5-9.4) (6.3-9.3) (2.1-6.0) (1.2-3.8) (1.9-3.6)
Rectum 37 10.4 17.1 11.6 6.6 8.5 3.9 2.0 4.7
(8.2-12.5) (14.5-19.8) (8.9-14.2) (4.7-8.4) (7.0-9.9) (2.6-5.3) (1.3-2.6) (2.9-6.8)
Stage (Dukes)
A 25 11.5 18.3 9.7 6.8 8.0 3.4 1.8 5.2
(8.9-14.1) (14.8-21.7) (6.8-12.5) (4.6-9.0) (6.5-9.5) (1.7-5.0) (1.0-2.6) (2.6-7.8)
B 45 10.6 17.1 10.5 6.5 6.9 3.0 2.0 3.1
(8.7-12.5) (14.5-19.6) (8.5-12.5) (4.5-8.4) (6.1-7.7) (2.2-3.7) (1.3-2.7) (2.4-3.9)
C 39 9.2 14.5 11.3 4.9 8.7 5.2 2.9 4.2
(7.0-11.4) (11.8-17.2) (8.6-14.1) (2.5-7.3) (7.1-10.2) (3.1-7.2) (1.6-4.3) (2.9-5.5)
Grade
Well 8 12.5 16.4 8.5 3.9 7.1 2.2 1.6 4.1
(7.9-17.1) (12.2-20.5) (4.4-12.6) (0.4-7.4) (5.2-8.9) (1.1-3.3) (0.8-2.4) (0.2-8.1)
Moderate 90 10.3 16.6 10.7 6.1 7.9 3.8 2.3 4.1
(8.9-11.6) (14.7-18.4) (9.1-12.2) (4.8-7.5) (7.1-8.7) (2.9-4.8) (1.7-2.9) (3.2-5.0)
Poor 11 9.5 16.3 11.7 6.8 6.8 3.7 1.8 2.5
(4.5-14.5) (10.4-22.3) (6.2-17.2) (0.7-13.0) (4.6-9.0) (1.0-6.5) (0.4-3.1) (0.7-4.3)
DNA ploidy
Diploid 39 12.2* 16.4 7.9** 4.0** 6.8* 3.0* 2.2 4.4*
(10.0-14.4) (13.7-19.1) (6.5-9.2) (2.1-5.9) (6.1-7.5) (2.0-4.0) (1.4-2.9) (3.3-5.4)
Aneuploid 51 9.3 17.3 12.7 7.8 8.5 4.3 2.2 3.6
(7.6-11.0) (14.9-19.8) (10.7-14.7) (6.0-9.6) (7.4-9.6) (3.2-5.5) (1.6-2.9) (2.5-4.8)
n, Number of colorectal cancers in each subgroup; LI/inv, labelling index at invasive margin; LI/lum, labelling index at luminal border; LI/fcm, labelling
index measured with flow cytometry alone; Diff., the difference between Li at luminal border and invasive margin, T,, S-phase time; Tp,,/inv, potential
doubling time measured with LI/IHC from the invasive margin; TP,0lum, potential doubling time measured with LI/IHC from the luminal border.
TP,/fcm, potential doubling time measured with flow cytometry alone. *P< 0.05 between groups of the same proliferative-associated parameter.
**P< 0.01 between groups of the same proliferative-associated parameter. Numbers within brackets represent 95% confidence intervals of the
mean. aLI/fcm from right colon was significantly lower than values from both left colon and rectum.
Concerning survival, no prognostic information was seen for
ploidy itself, either in the total unselected material (P = 0.8) or in
the group ofradically removed tumours (P = 0.6). With one excep-
tion (see below), the prediction of survival from parameters associ-
ated with cell proliferation (LI, T, T ), regardless of method of
evaluation (IHC and/or FCM), was not improved by taking ploidy
into account. This was valid for the entire material and for the
group with radically removed tumours. Survival analyses were not
carried out for the different Dukes' stages in combination with
ploidy status because of the small number of observations in the
respective groups. The exception was observed for patients with
diploid tumours showing very long T7 (highest quartile used as cut-
offlevel). Thesepatients had ahigher mortality rate than those with
shorter Ts-values (P < 0.001 for both the entire material and radi-
cally removed tumours). No significant difference in survival was
observed for T' when studying the group ofaneuploid tumours.
Clinicopathological parameters
With the exception of sex, topography and ploidy, none of the clini-
copathological parameters covaried with parameters associated with
proliferation (Table 1). LI/HIC at both the invasive margin and the
luminal border showed significant differences between the sexes;
where women had higher LIs than men (P = 0.02 and P = 0.02
respectively). Colorectal cancers in female patients had significantly
lower values of T A/IHC at the invasive margin compared with
colorectal cancers inmen (P=0.049). LI/FCM was also significantly
lowerin tumours derived from the right coloncompared with the left
colon and rectum. In contrast, LIIIHC did not differ according to
topography for the invasive margin or forthe luminal border.
DISCUSSION
The morphometric procedure used in this study is well known and
has been evaluated theoretically (Weibel, 1979). The technique
basically assumes a random, systematic sampling procedure and
focuses on counting a defined number of nuclei to provide a reli-
able mean value from each tumour (Gundersen et al, 1988; West
and Gundersen, 1990). The comparative test performed in our
laboratory, in which our standard non-random procedure of
sampling was compared with an optimal random systematic
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sampling, gave an excellent correlation, indicating that the results
obtained in this study were not significantly influenced by the
sampling procedure used. The definition of tumour compartments
corresponding to the invasive margin and to the luminal border
was done for practical reasons to standardize the morphometric
procedure.
Presence of heterogeneity is well known for many solid
tumours, including colorectal carcinomas. In this respect, the most
extensive studies concern DNA analyses, i.e. evaluation of ploidy
(Hiddemann et al, 1986; Scott et al, 1987) and S-phase fraction
(Quirke et al, 1985; Lindmark et al, 1991), but also to other
proliferative parameters such as PCNA (Teixeira et al, 1994) and
expression of Ki-67 (Shepherd et al, 1988). A few reports exist on
the presence of intratumoral heterogeneity with respect to LI/IHC
and T /IHC in renal cell carcinoma (Larsson et al, 1994) and to pot
T /FCM in colorectal cancer (Wilson et al, 1993b). Our study pot
describes the existence of a systematic heterogeneity within
colorectal cancer with more pronounced LI at the luminal border
compared with the invasive margin for a majority of colorectal
cancers. Such a proliferative difference in colorectal cancer is
supported by reports after in vitro labelling (LI/IHC) with BrdUrd
(Taniyama et al, 1993) and by distribution of Ki-67 tumour cell
LI combined with endothelial cell proliferative heterogeneity
(Vermeulen et al, 1995).
Evaluation ofproliferation with FCM after in vivo incorporation
of IdUrd does not in practice allow the different defined tumour
compartments to be analysed separately. In addition, it is difficult
to distinguish between tumour and non-tumour cells, at least in
diploid tumours, because of the admixture ofnormal, less prolifer-
ative cells (Wilson et al, 1991). The more reliable measurements of
LI with IHC suggest that LI at the invasive margin is, in compar-
ison with LI/FCM, rather the reverse, with higher LI in diploid
than in aneuploid tumours. In contrast, when analysing the LI/IHC
at the luminal border, no difference between diploid and aneuploid
tumours was observed.
Speculatively, there are two possible major explanations for the
difference in proliferation between the luminal border and the
invasive margin, although these explanations are not mutually
exclusive.
On the one hand, feacal content is known to stimulate cell
proliferation and, therefore it seems reasonable that the prolifera-
tion rate would be higher at the luminal border and that the prolif-
erative activity would decrease when the diffusion distance from
the feacal factors increases. Such proliferative stimulators are, for
example, secondary bile acids, mainly lithocholic acid, other
steroid-derived compounds, short-chain fatty acids and the direct
influence from the bacterial content (Mullan et al, 1990).
However, local non-specific regenerative factors from the ulcera-
tive process at the luminal border can also increase the luminal
proliferative activity.
On the other hand, tumour cells growing at the invasive margin
might be more influenced by factors produced by the surrounding
stromal cells rather than by cells at the luminal border. Such an
influence includes differences in local levels ofgrowth factors, e.g.
transforming growth factor beta (TGF-P). TGF-P has several
diverse fields of action in normal cells, eg. decreasing prolifera-
tion, increasing differentiation, increasing apoptosis and stimu-
lating angiogenesis (Lawrence et al, 1996). The correlation
between decreased proliferation and a higher mortality rate
observed in this study could be in accordance with some of the
effects of TGF-P. The total action ofTGF-P is, however, highly
complex and not completely understood. Other factors affecting
proliferation of tumour cells are also released from the stromal
cells and some of them are known to interfere with the cell cycle.
This suggests a possible mechanism for the decreased proliferative
activity at the invasive margin.
Tumour cells with invading behaviour require high rates of
protein synthesis but are not dependent on DNA synthesis and
proliferation (Thorgeirsson et al, 1984). In addition, in malignant
gliomas, it is believed that tumour cells must cease proliferation to
be able to invade the surrounding tissue (Pilkington et al, 1992).
The extracellular matrix proteins seem to inhibit the proliferation
of glioma cells and instead stimulate them to migrate
(Koochekpour et al, 1995). In addition to these two possible expla-
nations, the presence of separate cell clones at the luminal border
and at the invasive margin, and problems of nutrient and oxygen
delivery to the invasive margin cannot be excluded.
The systematic heterogeneity observed in this study has impli-
cations for sampling when cell kinetic parameters are to be evalu-
ated. As LIs at the luminal border and invasive margin are well
correlated, cell kinetic evaluation of samples taken regularly from
either of these compartments seems rational. Analyses of
randomly extracted samples from colorectal cancers may,
however, be of less value.
The prognostic impact of cell kinetic data in colorectal cancer
remains questionable. Concerning S-phase fraction, results both
with (Bauer et al, 1987; Witzig et al, 1991) and without (Enker et al,
1991) significant prognostic impact have been published;Therefore,
according to the consensus by Baueret al (1993) doubts remain as to
whether the S-phase fraction can contribute to the prediction of
outcome for patients with colorectal cancer. Cell kinetic studies of
colorectal carcinoma using other cell cycle associated parameters
are sparse. Rew et al (1993) studied colorectal cancer after in vivo
incorporation of BrdUrd and did not find any prognostic impact of
flow cytometric evaluation ofTPot. Morphometric analysis of Ki-67
after immunohistochemical staining of routinely fixed, paraffin-
embedded tumour samples (Kubotaetal, 1992; Baretton etal, 1996)
also failed to predict the outcome.
In contrast to previous reports, our data indicate a negative
influence from cell proliferation after IdUrd incorporation in vivo,
significant for LI/IHC and T /IHC in the unselected group of
colorectal cancers. One conceivable explanation for the observed
impact on prognosis could be the morphometric control of the
systematic heterogeneity that exists between the luminal compart-
ment and the invasive margin in our study (extensively discussed
by Rew et al (1993). The negative prognostic impact from cell
proliferation after in vivo incorporation of IdUrd observed in this
study, i.e. shorter survival for colorectal cancer with a low LI or
long Tpt compared with tumours with high LI and short T,t, has to
the best of our knowledge not been reported earlier. However,
morphometrical evaluation of PCNA in a group of advanced
colorectal cancers also showed a correlation between low PCNA
LI/IHC and poorerprognosis (Paradiso et al, 1996). Decreased cell
proliferation corresponding to lowerLIIIHC after in vitro incorpo-
ration ofBrdUrd in diploid colorectal cancers has previously been
correlated with increased numbers of regional lymph node metas-
tases (Taniyama et al, 1993). Furthermore, low LI/IHC for PCNA
and Ki-67 correlate to areas with low differentiation at the invasive
margin ofcolorectal cancer (Taniyama et al, 1996). A recent study
of cell proliferation in breast cancer also indicates a connection
between positive survival outcomes after treatment and high
LI/IHC after BrdUrd incorporation (Gamel et al, 1995).
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This study provides new insight into the biological behaviour of
colorectal cancer. Therefore, additional studies with IdUrdlBrdUrd
and other cell cycle-associated parameters, such as Ki-67, are
important, provided that the problem ofheterogeneity is taken into
account.
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